Bioceltix Cash Flow Statement

Financials in millions PLN. Fiscal year is January - December.

Millions PLN. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-13.85	-14.9	-13.69	-8.92	-4.4
Depreciation & Amortization	0.72	0.57	0.43	0.45	0.38
Loss (Gain) From Sale of Assets	0.06	-0.05	-	-0.05	-0.07
Other Operating Activities	0.22	0.17	0.03	0.03	0.02
Change in Accounts Receivable	1.06	-3.09	-1.51	0.22	-0.25
Change in Inventory	0.02	-0.01	-0.01	-	0.01
Change in Other Net Operating Assets	-1.55	-0.27	-0.01	0.41	0.29
Operating Cash Flow	-13.34	-17.57	-14.75	-7.87	-4.02
Capital Expenditures	-0.8	-0.24	-0.46	-0.35	-0.01
Sale of Property, Plant & Equipment	0.03	0.16	-	-	0.14
Investing Cash Flow	-0.77	-0.08	-0.46	-0.35	0.13
Long-Term Debt Repaid	-	-0.71	-0.12	-0.21	-0.42
Net Debt Issued (Repaid)	-0.93	-0.71	-0.12	-0.21	-0.42
Issuance of Common Stock	25.27	42.85	20.67	6.53	7.17
Other Financing Activities	-0.22	-0.17	-0.15	-0.03	-0.02
Financing Cash Flow	24.12	41.97	20.4	6.29	6.74
Net Cash Flow	10.01	24.32	5.19	-1.93	2.85
Free Cash Flow	-14.14	-17.81	-15.21	-8.23	-4.02
Free Cash Flow Per Share	-2.87	-3.93	-3.88	-2.47	-1.27
Cash Interest Paid	0.17	0.17	0.03	0.03	0.02
Levered Free Cash Flow	12.99	-12.61	-8.89	-6.36	-
Unlevered Free Cash Flow	13.12	-12.5	-8.87	-6.34	-
Change in Working Capital	-0.47	-3.36	-1.53	0.62	0.05

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.